News
Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
Merck has reached a $10 billion deal to acquire Verona Pharma, a biotech whose first-in-class drug is already commercialized in one prevalent lung disorder and is showing promise in other ...
U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...
Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results